In a significant development for mental healthcare, the U.S. FDA has approved Teva Pharmaceuticals’ IGALMI (dexmedetomidine) sublingual film for at-home use, making it the first FDA-approved treatment that adults can use at home for agitation associated with schizophrenia, schizoaffective disorder, and bipolar I or II disorder.
The approval marks a major expansion of treatment options for patients and caregivers dealing with acute agitation, which can escalate rapidly and often requires urgent medical intervention.
IGALMI, developed by Teva Pharmaceutical Industries Ltd.’s U.S. affiliate, offers a new option for managing agitation outside clinical settings, potentially helping patients access treatment when symptoms emerge rather than waiting until an episode becomes a medical emergency.
“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” said Chris Fox, Executive Vice President, U.S. Commercial and Head of Innovative Franchise at Teva.
“With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it, reflecting Teva’s commitment to improving how care is experienced in everyday life.”
The need for additional treatment options is substantial. Agitation affects an estimated 25% to 40% of patients across schizophrenia, schizoaffective disorder, and bipolar I or II disorder. Acute episodes can create serious challenges for patients, families and caregivers, with up to 21% of cases resulting in an emergency department visit or hospitalization.
Teva said the approval reflects a broader effort to rethink how and where treatments for neurological and psychiatric conditions are delivered.
“Innovation in neuroscience is about discovering new medicines and also about rethinking when, where and how treatment can be delivered,” said Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”
The FDA approval is supported by findings from the Phase 3 SERENITY At-Home Safety and Tolerability Trial. During the 12-week study, 102 patients treated 1,160 agitation episodes with IGALMI. Researchers reported that tolerability remained consistent with repeat dosing throughout the study period.
The most commonly reported adverse events, occurring in at least 5% of patients and at a higher rate than placebo, included somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia. No patients discontinued treatment because of tolerability issues in the Phase 3 SERENITY At-Home Trial.
Teva acquired IGALMI in late October 2026. The company submitted its supplemental New Drug Application (sNDA) for at-home use to the FDA on January 14, 2026, building on the existing IGALMI approval for use under the supervision of a healthcare provider.
The company said it will announce its commercialization plans for the at-home indication at a later date.